Browsing by Author "Rojas, P"

Now showing 1 - 3 of 3
  • No Thumbnail Available
    Item
    High prevalence of undiagnosed primary hyperaldosteronism among patients with essential hypertension
    (1999) Mosso, L; Fardella, C; Montero, J; Rojas, P; Sanchez, O; Rojas, V; Rojas, A; Huete, A; Soto, J; Foradori, A; NCD Risk Factor Collaboration (NCD-RisC)
    Background: Classically, primary hyperaldosteronism was diagnosed in no more than 1% of patients with hypertension, when hypokalemia was used as the screening test. However, numerous patients with primary hyperaldosteronism do not have hypokalemia nod the disease remains undiagnosed. Aim: To assess the prevalence of normokalemic primary hyperaldosteronism among patients classified as having essential hypertension. Patients and methods: One hundred hypertensive patients with a blood pressure over 145/95 were studied. Plasma aldosterone and plasma renin activity were measured in all. A primary hyperaldosteronism was diagnosed when high aldosterone levels (over 16 ng/dl) and low plasma renin activity (below 0.5 ng/ml/h) coexisted in two blood tests of the aldosterone/plasma renin activity ratio was over 50. A probable primary hyperaldosteronism was diagnosed whet? the ratio was between 25 and 50 and these patients were subjected to a Fludrocortisone test to confirm the diagnosis. A dexametasone suppression test was done to discard glucocorticoid remediable aldosteronism. An adrenal TAC scan was done to all patients with primary hyperaldosteronism. Results: A diagnosis of primary hyperaldosteronism was reached in ten patients. Seven had elevated aldosterone and low plasma renin activity. In three the diagnosis was confirmed with the fludrocortisone test. All ten patients had normal serum potassium levels. Dexametasone suppression test was positive in three patients that normalized their blood pressure levels. Adrenal TAC scans showed an adenoma in one patient and hyperplasia in another. Conclusions: Primary hyperaldosteronism is more frequent than previously thought, it is overlooked when hypokalemia is used as the screening test and it can only be diagnosed measuring plasma aldosterone and renin activity.
  • No Thumbnail Available
    Item
    Normokalemic primary hyperaldosteronism - A common cause of secondary hypertension.
    (1999) Mosso, L; Fardella, C; Montero, J; Rojas, P; Sanchez, O; Rojas, A; Soto, J; Foradori, A; Huete, A; NCD Risk Factor Collaboration (NCD-RisC)
    Recently, some genetic forms of hypertension have been well characterized. These forms can be globally called mineralocorticoid hypertension and are due to different alterations of the renin-angiotensin-aldosterone system (SRAA). Among these, classic primary hyperaldosteronism and its glucocorticoid remediable variety, in which hypertension is secondary to aldosterone production, must be considered. There are also conditions in which mineralocorticoid activity does not depend on aldosterone production. These conditions generate a hyporeninemic hyperaldosteronism, observed in Liddle syndrome, apparent mineralocorticoid hypertension, 11- and 17-hydroxilase deficiency, among others. The detection of these forms of hypertension is only feasible if the renin-angiotensin-aldosterone system is assessed, measuring renin and aldosterone levels. This article reviews these forms of hypertension, their clinical workup and their relevance in the usual hypertensive patients.
  • Thumbnail Image
    Item
    Prevalence of heparin-induced antibodies in patients with chronic renal failure undergoing hemodialysis
    (WILEY, 2005) Palomo, I; Pereira, J; Alarcon, M; Diaz, G; Hidalgo, P; Pizarro, I; Jara, E; Rojas, P; Quiroga, G; Moore Carrasco, R
    Heparin-induced thrombocytopenia (HIT) type II is a serious complication of heparin therapy. It presents initially as thrombocytopenia, and is associated with thrombosis in 20-50% of the cases. HIT is related to the presence of heparin-induced antibodies (HIA), which show specificity for the PF4-heparin (PF4-H) complex. The Fc gamma RIIa receptor has been suggested to participate in the pathogenic mechanism of HIA. Since patients undergoing chronic hemodialysis (HD) are exposed repeatedly to heparin, we studied the prevalence of HIA and their eventual relationship with thrombocytopenia and/or thrombosis, and the possible participation of the Fc gamma RIIa polymorphism. We studied 207 patients with chronic renal failure (CRF) undergoing HID. As a control we included 130 blood donors and 28 patients with CRF without HID. The HIA patients were studied with the use of a PF4-H ELISA. Additionally, in some positive cases for the previous test, a C-14- serotonin release assay (C-14-SRA) was performed. The polymorphism Fc gamma RIIa H/R131 was studied by polymerase chain reaction (PCR) with allele-specific primers. Thirty-seven patients (17.9%) undergoing HD presented with HIA. The majority of these antibodies were IgG, IgM, and IgA. The HIA investigated presented specificity against the PF4-H complex, but not against PF4 alone (P < 0.001). Twelve out of 22 (54.5%) PF4-H antibodies were positive when tested with the C-14-SRA. The distribution of the Fc gamma RIIa polymorphism in patients and healthy controls was 42.6% and 41.6% for H/H131, 41% and 48.9% for the H/R131 isoform, and 16.4% and 9.5% for the R/R131 isoform, respectively. No statistically significant difference in the Fc gamma RIIa isoform distribution was found. Twenty-nine out of 156 patients (18.5%) presented thrombocytopenia, and 21/207 (12.4%) had thrombosis of the native vein arterio-venous fistula (AVF). We did not find any statistically significant between HIA and thrombocytopenia or thrombosis. An important proportion of patients with CRF undergoing HD developed HIA, but these cases were not associated with thrombocytopenia or thrombosis of AVF. The frequency of the Fc gamma RIIa polymorphism did not statistically differ between HIT type II and normal controls.